Ani Pharmaceuticals, Inc. · NASDAQ:ANIP
Ani Pharmaceuticals — Investor Presentation (May 2016)
24 slides from Ani Pharmaceuticals's investor presentation, May 18, 2016
Slide 1: Corporate Presentation May 2016
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation May 2016
Slide 2: Forward-Looking Statements
Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statem
Slide 3: ANI Mission Statement
3 ANI Mission Statement ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals. We focus on niche and high barrier to entry opportunities including controlled substances, anti - cancer (oncolytics
Slide 4: ANI Senior Management Team
ANI Senior Management Team 4 At ANI Since Yrs Industry Experience Arthur Przybyl President and CEO 2009 25+ Stephen Carey VP and CFO 2016 20+ Robert Schrepfer VP of Bus. Development 2013 15 Jim Marken VP of Operations 2007 20+ David Sullivan VP of Quality Operations 2014 20
Slide 5: ANI Overview – Positioned for Growth
ANI Overview – Positioned for Growth ANI Today ▪ Current business – For the quarter ended March 31, 2016: $20.6 million total net revenues □ $13.3 million Generic Rx product revenues □ $5.6 million Brand Rx product revenues □ $1.7 million c ontract manufacturing/services revenues □ Growth of 9% quar
Slide 6: ANI Financial Highlights
ANI Financial Highlights 6 First Quarter 2016 Results ($ in millions) Quarter ended March 31, 2016 March 31, 2015 % Growth Net revenues $ 20.6 $ 18.8 9 % Adjusted non - GAAP EBITDA (1) $ 11.4 $ 11.5 - (1) Please see Appendix A for US GAAP reconciliation 2015 Results ($ in millions) Year ended Decemb
Slide 7: ANI Revenue and EBITDA Historical Growth
ANI Revenue and EBITDA Historical Growth 7 $s in millions
Slide 8: Sales and Marketing Overview
8 Sales and Marketing Overview
Slide 9: ANI Generic Rx Product Portfolio
ANI Generic Rx Product Portfolio EE/MT Tablets Etodolac Capsules Fenofibrate Capsules (AG) Flecainide Tablets Fluvoxamine Tablets (AG) HC Cream, for rectal use HC Enema (AG) Mesalamine Enema (AG) Methazolamide Tablets Metoclopramide Solution Nimodipine Capsules Opium Tincture Oxycodone Solution Prop
Slide 10: ANI Brand Rx Product Portfolio
ANI Brand Rx Product Portfolio 10 Lithobid ® Tablets Bipolar Disorder Vancocin ® Capsules C. difficile - Associated Diarrhea Cortenema ® U lcerative Colitis Reglan ® Gastroesophageal Reflux Q1 2016 Net Sales: $5.6M Inderal ® LA Hypertension Launched April 2016
Slide 11: ANI Contract Manufacturing and Other Current Business
ANI Contract Manufacturing and Other 11 Current Business ▪ Four customers – Seven products and seventeen SKUs – Contract manufacturing and contract packaging Q1 2016 Net Sales: $1.7M
Slide 12: Business Development / Product Development Overview
12 Business Development / Product Development Overview
Slide 13: Business Development Activity - Generics
Business Development Activity - Generics 13
Slide 14: Business Development Activity - Brands
Business Development Activity - Brands 14
Slide 15: ANI Product Development Pipeline
15 ANI Product Development Pipeline 81 p roducts in development, total combined current market: $4.1 billion (1) ▪ 55 products were acquired and of those, ANI believes 48 can be commercialized based on either a CBE - 30 or PAS ▪ New product introductions: (1) Based on Company estimates, and recent I
Slide 16: Manufacturing Overview
16 Manufacturing Overview
Slide 17: ANI Manufacturing – Main Street Facility
17 ANI Manufacturing – Main Street Facility Location: Baudette , Minnesota ▪ 52,000 square feet of manufacturing , packaging, and warehouse facilities ▪ Rx solutions , suspensions , topicals , tablets , and capsules ▪ DEA - licensed for Schedule II controlled substances ▪ 17,000 square feet of labor
Slide 18: ANI Manufacturing – IDC Road Facility
18 ANI Manufacturing – IDC Road Facility Location: Baudette, Minnesota ▪ Fully - contained h igh potency facility with capabilities to manufacture h ormone , steroid , and oncolytic products ▪ 47,000 square feet of manufacturing and packaging, and warehouse facilities ▪ 100 nano - gram per eight - h
Slide 19: ANI Summary
ANI Summary ANI is an integrated specialty generic pharmaceutical firm with: ▪ Profitable base business generating organic growth – 2016 Annual guidance (1) □ Net revenues of $119 million to $134 million □ Adjusted non - GAAP EBITDA (2) of $55 million to $63 million □ Adjusted non - GAAP Net Income
Slide 20: Appendix A
20 Appendix A
Slide 21: U.S. GAAP Reconciliations
U.S. GAAP Reconciliations 21 2016 2015 Operating Income 5,666$ 9,567$ Add back Depreciation and amortization 4,609 1,327 Add back Stock-based compensation 1,105 568 Adjusted non-GAAP EBITDA 11,380$ 11,462$ ANI Pharmaceuticals, Inc. and Subsidiaries Adjusted non-GAAP EBITDA Calculation and US GAAP to
Slide 22: U.S. GAAP Reconciliations
U.S. GAAP Reconciliations 22 2016 2015 Net Income 1,346$ 4,369 Add back Tax provision 1,540 2,541 Depreciation and amortization expense 4,609 1,327 Non-cash interest expense 1,725 1,683 Stock-based compensation 1,105 568 Excess of Fair Value over Cost of Acquired Inventory - - Less Current portion o
Slide 23: U.S. GAAP Reconciliations
U.S. GAAP Reconciliations 23 2015 2014 Operating Income $32,700 $20,006 Add back Depreciation and amortization 6,900 3,878 Add back Stock-based compensation 3,856 3,423 Adjusted non-GAAP EBITDA $43,456 $27,307 ANI Pharmaceuticals, Inc. and Subsidiaries Adjusted non-GAAP EBITDA Calculation and US GAA
Slide 24: U.S. GAAP Reconciliations
U.S. GAAP Reconciliations 24 2015 2014 Net Income $ 15,375 $ 28,747 Add back Tax provision 6,358 (9,368) Depreciation and amortization expense 6,900 3,878 Non-cash interest expense 6,831 560 Stock-based compensation 3,856 3,423 Excess of Fair Value over Cost of Acquired Inventory - 29 Less Current p
ANI Pharmaceuticals — Investor Presentation (May 2016) on 6ix